Dr. Mike Owen has worked in biomedical research and in the pharmaceutical and biotechnology industries for nearly 40 years. In addition to GammaDelta Therapeutics, he is the Chairman of Ossianix, while also sitting on the Boards of Zealand Pharma, Avacta plc, ReNeuron plc, Sareum plc and Iksuda Therapeutics. He is Chairman of Reneuron’s and Avacta’s Science Advisory Boards. In addition, Mike is an observer on the Investment and Divestment Committee of the Cancer Research Technology Pioneer Fund and advisor to Abingworth.
Mike co-founded biopharmaceutical company Kymab, where he served as its first Chief Scientific Officer. Prior to this, he worked for GSK as the Senior Vice President and Head of Research for Biopharmaceuticals R&D.
Mike received a BA degree from the University of Oxford and a PhD from the University of Cambridge. He was elected a member of the European Molecular Biology Organisation and a Fellow of the Academy of Medical Sciences.